Consideration of individual bioequivalence
- 1 June 1990
- journal article
- research article
- Published by Springer Nature in Journal of Pharmacokinetics and Biopharmaceutics
- Vol. 18 (3) , 259-273
- https://doi.org/10.1007/bf01062202
Abstract
Current procedures for assessing the bioequivatence of two formulations are based on the concept of average bioequivalence. That is, they assess whether the average responses between individuals on the two formulations are similar. Average bioequivalence, however, is not sufficient to guarantee that an individual patient could be expected to respond similarly to the two formulations. To have reasonable assurance that an individual patient could be switched from a therapeutically successful formulation to a different formulation (e.g., a generic substitute) requires a different notion of bioequivalence, which we refer to as individual (or within-subject) bioequivalence. We propose a simple, valid statistical procedure for assessing individual bioequivalence. The decision rule, TIER (Test of Individual Equivalence Ratios), requires the specification of the minimum proportion of subjects in the applicable population for which the two formulations being tested must be bioequivalent (a regulatory decision). The TIER rule is summarized in terms of the minimum number of subjects with bioavailability ratios falling within the specified equivalence interval necessary to be able to claim bioequivalence for given sample size and Type I (α) error. We recommend that the corresponding lower bounds (one-sided confidence intervals) for the proportion of bioequivalent subjects be calculated. TIER is partly motivated by the U.S. FDA's 75/75 Rule (at least 75% of the individual subject bioavailability ratios must be within 75–125%). TIER retains the sensible idea of considering the individual ratios but, unlike the 75/75 rule, is a statistically valid procedure.Keywords
This publication has 8 references indexed in Scilit:
- A new statistical procedure for testing equivalence in two-group comparative bioavailability trialsJournal of Pharmacokinetics and Biopharmaceutics, 1984
- A new procedure for testing equivalence in comparative bioavailability and other clinical trialsCommunications in Statistics - Theory and Methods, 1983
- Statistical Methods for Bioavailability and BioequivalenceClinical Research Practices and Drug Regulatory Affairs, 1983
- Assessment of 75/75 Rule: FDA ViewpointJournal of Pharmaceutical Sciences, 1983
- The Bioavailability of Erythromycin Stearate versus Enteric-Coated Erythromycin Base When Taken Immediately before and after FoodJournal of International Medical Research, 1981
- Statistical Simulation Study of New Proposed Uniformity Requirement for Bioequivalency StudiesJournal of Pharmaceutical Sciences, 1981
- Statistical Aspects of Comparative Bioavailability TrialsBiometrics, 1979